Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

0.4713 -0.0387 (-7.59%)
Streaming Delayed Price Updated: 10:44 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bioxcel Therapeutics Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Recap: BioXcel Therapeutics Q4 Earnings
BioXcel Therapeutics (NASDAQ:BTAI) reported its Q4 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate Cancer
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced results from its ongoing Phase 2 trial of BXCL701 in metastatic castration-resistant prostate cancer (mCRPC) patients with... 
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
FDA Pushes Review Of BioXcel's Candidate For Agitation Associated With Neuropsychiatric Disorders
The FDA has extended the review period for BioXcel Therapeutics Inc's (NASDAQ: BTAI) marketing application seeking approval for BXCL501 for the acute... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Ardelyx (NASDAQ:ARDX) stock increased by 19.29% to $1.36 during Wednesday's pre-market session. The market value of their outstanding shares is at $153.3... 
Via Benzinga
Why BioXcel Therapeutics Is Down Sharply This Week
A double downgrade from an analyst on Wall Street is causing investors to think twice about the company's first new drug launch. 
Via The Motley Fool
70 Biggest Movers From Yesterday
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The... 
Via Benzinga
Mid-Afternoon Market Update: Telos Falls After Q3 Results; Creative Realities Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.05% to 36,082.17 while the NASDAQ fell 0.35% to 15,806.01. The S&P also fell, dropping 0.11% to 4,677.64. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why BioXcel Therapeutics Stock Is Crashing Today
An analyst downgraded the stock. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Tricida (NASDAQ:TCDA) shares rose... 
Via Benzinga
Mid-Day Market Update: Nasdaq Turns Lower; Casper Sleep Shares Jump
Midway through trading Monday, the Dow traded up 0.05% to 36,117.49 while the NASDAQ fell 0.29% to 15,815.61. The S&P also fell, dropping 0.06% to 4,679.81. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
41 Stocks Moving In Monday's Mid-Day Session
Gainers Casper Sleep Inc. (NYSE: CSPR) shares climbed 87.1% to $6.64 after the company agreed to be acquired by Durational Capital Management. The company also reported Q3... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Tyson Foods Posts Upbeat Q4 Results
Following the market opening Monday, the Dow traded up 0.27% to 36,196.19 while the NASDAQ rose 0.26% to 15,902.90. The S&P also rose, gaining 0.24% to 4,693.92. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021
Upgrades For Targa Resources Corp (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers EyePoint Pharmaceuticals (NASDAQ:EYPT) stock increased by 44.96% to $20.31 during Monday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, trader! We're getting right into the thick of it this week with a look at the biggest pre-market stock movers for Monday! 
Via InvestorPlace
10 Biggest Price Target Changes For Monday
Keybanc boosted the price target on Netflix, Inc. (NASDAQ: NFLX) from $690 to $725. Netflix shares rose 0.2% to $683.90 in pre-market trading. Piper Sandler raised the price... 
Via Benzinga
This High-Risk, High-Reward Stock Might Double Your Money
After a difficult year, shares of this biotech could bounce back big. 
Via The Motley Fool
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Exposures COVID-19
44 Biggest Movers From Yesterday
Gainers Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday. Grove, Inc. (NASDAQ: GRVI) gained 39.3% to close at $6.98 after... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP... 
Via Benzinga
Why BioXcel Therapeutics Stock Is Sinking Today
The company's chief commercial officer resigned. 
Via The Motley Fool
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
This Under-the-Radar Dementia Treatment Could Reward Investors
Want to dabble in the market for Alzheimer's therapies but avoid Biogen? Look no further. 
Via The Motley Fool
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.